Abstract 1821P
Background
Cardiovascular disease (CVD) is a leading cause of death in men with prostate cancer (PC). Androgen deprivation therapy (ADT) may increase this risk. GnRH agonists or antagonists induce equivalent castration but have a distinctive effect on follicle-stimulating hormone (FSH). We hypothesize that FSH mediates the atherogenic and cardiovascular effects associated with testosterone (T) deficiency.
Methods
We investigated mouse models of atherosclerosis using gain and loss of FSH and two clinical studies with primary CVD endpoints. Low-density lipoprotein receptor-deficient (LDLR-/-) and FSHβ-/-;LDLR-/- mice were treated with different modes of ADT for 14 weeks and aortic atherosclerotic plaque, its necrotic and inflammatory content and serum hormones were determined. In a prospective cohort of PC patients commencing on ADT, serum FSH and T were determined after three and six months and related to the development of cardiovascular events. In a prospective nested case-control study of 848 men undergoing surgery, serum FSH and T were related to the development of cardiovascular event.
Results
Compared to LDLR-/- mice, FSHβ-/-;LDLR-/- mice, untreated or castrated, demonstrated significantly less atherosclerosis, but not following delivery of FSH. The significant differences in necrotic core and total atherosclerotic plaque in mice treated with GnRH-agonists vs. antagonists were nullified by loss of FSH in the FSHβ-/-;LDLR-/- mice. Atherosclerotic plaque, its necrotic and inflammatory content, correlated significantly with the serum FSH/T ratio. In PC patients commencing on ADT, serum FSH/T after three and six months significantly predicted the development of cardiovascular event. In men undergoing surgery, high FSH/T ratio increased odds of a postoperative cardiovascular event by 39% (95% CI 3-87%).
Conclusions
FSH facilitates CVD in men with low or castrated T. Serum FSH/T ratio associates with the risk of developing a cardiovascular event following a stressful cardiovascular trigger such as ADT or surgery. Accordingly, GnRH-antagonists associated with lower necrotic and atherosclerotic plaque burden in mice and clinically, with significantly lower serum FSH/T levels and fewer cardiovascular events compared to GnRH-agonists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. H. Pinthus.
Funding
Ferring.
Disclosure
J.H. Pinthus, D. Margel: Financial Interests, Personal, Research Grant: Ferring. All other authors have declared no conflicts of interest.
Resources from the same session
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15
1840P - RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Juliet Carmichael
Session: Poster session 15